<p>Tarsus Pharmaceuticals, Inc.（纳斯达克代码：TARS - 获取免费报告）在周一的交易中，其股价达到了新的 52 周高点。该股最高交易价为 57.14 美元，最后交易价为 56.17 美元，成交量为 228758 股。该股此前收盘价为 55.00 美元。</p>
<p>获取 <strong>Tarsus Pharmaceuticals</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>多家券商对 TARS 发布了报告。Oppenheimer 将 Tarsus Pharmaceuticals 的目标价从 63.00 美元上调至 65.00 美元，并在 11 月 14 日的报告中给予该股 “跑赢大盘” 的评级。高盛集团将 Tarsus Pharmaceuticals 的目标价从 36.00 美元上调至 41.00 美元，并在 11 月 15 日的报告中给予该公司 “中性” 的评级。一位股票研究分析师对该股给予了持有评级，四位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，平均目标价为 54.20 美元。</p>
<p><strong>阅读我们关于 TARS 的最新报告</strong></p>
<h2>Tarsus Pharmaceuticals 价格表现</h2>
<p>该公司的市值为 21.4 亿美元，市盈率为-14.67，贝塔值为 1.04。该公司的流动比率为 5.42，速动比率为 5.38，债务权益比为 0.30。该公司的 50 日移动平均价格为 48.24 美元，200 日移动平均价格为 35.82 美元。</p>
<h2>机构投资者对 Tarsus Pharmaceuticals 的看法</h2>
<p>多家机构投资者和对冲基金最近增加或减少了在 TARS 的持股。Quest Partners LLC 在第二季度以 61,000 美元的估值收购了 Tarsus Pharmaceuticals 的新股份。加拿大养老金计划投资委员会在第二季度以 114,000 美元的估值收购了 Tarsus Pharmaceuticals 的新股份。FMR LLC 在第三季度将其在 Tarsus Pharmaceuticals 的持股增加了 236.6%。FMR LLC 目前拥有 5,032 股该公司的股票，价值 166,000 美元，此前在此期间又购买了 3,537 股。苏黎世州立银行在第二季度将其在 Tarsus Pharmaceuticals 的持股增加了 33.4%。苏黎世州立银行目前拥有 6,109 股该公司的股票，价值 166,000 美元，此前在上个季度又购买了 1,530 股。最后，SG Americas Securities LLC 在第三季度将其在 Tarsus Pharmaceuticals 的持股增加了 87.5%。SG Americas Securities LLC 目前拥有 7,242 股该公司的股票，价值 238,000 美元，此前在此期间又购买了 3,379 股。对冲基金和其他机构投资者持有该公司 90.01% 的股票。</p>
<h2>Tarsus Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Tarsus Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于在美国开发和商业化新型眼科治疗候选药物。该公司的主要产品候选药物是 XDEMVY，一种用于治疗由螨虫感染引起的睑板腺炎的新型治疗药物，以及用于治疗睑板腺疾病。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Tarsus Pharmaceuticals</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>2025 年必须持有的三只股票，具有两位数的上涨潜力</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>美光：为什么现在是勇敢的时候</li>
<li>如何投资 FAANG 股票</li>
<li>三只华尔街内部人士无法停止购买的股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<p>→ 释放病毒特朗普视频（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE0NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE0NQ"/></p>
<h2>你现在应该投资 1,000 美元在 Tarsus Pharmaceuticals 吗？</h2>
<p>在你考虑 Tarsus Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tarsus Pharmaceuticals 并不在名单上。</p>
<p>虽然 Tarsus Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

TARS

<p>Tarsus Pharmaceuticals（纳斯达克代码：TARS）在交易中达到了新的 52 周高点 57.14 美元，收盘价为 56.17 美元。分析师们提高了价格目标，Oppenheimer 将其目标上调至 65.00 美元，高盛则上调至 41.00 美元。该股票的共识评级为 “买入”，平均价格目标为 54.20 美元。机构投资者持有该股票的 90.01%，公司专注于开发眼科治疗，特别是其主要产品 XDEMVY 用于治疗睑炎</p>

<p>Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $57.14 and last traded at $56.17, with a volume of 228758 shares trading hands. The stock had previously closed at $55.00.</p>
<div class="lb-trans"><p>Tarsus Pharmaceuticals, Inc.（纳斯达克代码：TARS - 获取免费报告）在周一的交易中，其股价达到了新的 52 周高点。该股最高交易价为 57.14 美元，最后交易价为 56.17 美元，成交量为 228758 股。该股此前收盘价为 55.00 美元。</p>
</div><p>Get <strong>Tarsus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tarsus Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages have issued reports on TARS. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, November 14th. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and an average price target of $54.20.</p>
<div class="lb-trans"><p>多家券商对 TARS 发布了报告。Oppenheimer 将 Tarsus Pharmaceuticals 的目标价从 63.00 美元上调至 65.00 美元，并在 11 月 14 日的报告中给予该股 “跑赢大盘” 的评级。高盛集团将 Tarsus Pharmaceuticals 的目标价从 36.00 美元上调至 41.00 美元，并在 11 月 15 日的报告中给予该公司 “中性” 的评级。一位股票研究分析师对该股给予了持有评级，四位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，平均目标价为 54.20 美元。</p>
</div><p><strong>Read Our Latest Report on TARS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 TARS 的最新报告</strong></p>
</div><h2>Tarsus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 价格表现</h2>
</div><p>The firm has a market capitalization of $2.14 billion, a PE ratio of -14.67 and a beta of 1.04. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a fifty day moving average price of $48.24 and a two-hundred day moving average price of $35.82.</p>
<div class="lb-trans"><p>该公司的市值为 21.4 亿美元，市盈率为-14.67，贝塔值为 1.04。该公司的流动比率为 5.42，速动比率为 5.38，债务权益比为 0.30。该公司的 50 日移动平均价格为 48.24 美元，200 日移动平均价格为 35.82 美元。</p>
</div><h2>Institutional Investors Weigh In On Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Tarsus Pharmaceuticals 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in TARS. Quest Partners LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $61,000. Canada Pension Plan Investment Board acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at $114,000. FMR LLC increased its stake in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after purchasing an additional 3,537 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after buying an additional 1,530 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock worth $238,000 after buying an additional 3,379 shares during the period. Hedge funds and other institutional investors own 90.01% of the company's stock.</p>
<div class="lb-trans"><p>多家机构投资者和对冲基金最近增加或减少了在 TARS 的持股。Quest Partners LLC 在第二季度以 61,000 美元的估值收购了 Tarsus Pharmaceuticals 的新股份。加拿大养老金计划投资委员会在第二季度以 114,000 美元的估值收购了 Tarsus Pharmaceuticals 的新股份。FMR LLC 在第三季度将其在 Tarsus Pharmaceuticals 的持股增加了 236.6%。FMR LLC 目前拥有 5,032 股该公司的股票，价值 166,000 美元，此前在此期间又购买了 3,537 股。苏黎世州立银行在第二季度将其在 Tarsus Pharmaceuticals 的持股增加了 33.4%。苏黎世州立银行目前拥有 6,109 股该公司的股票，价值 166,000 美元，此前在上个季度又购买了 1,530 股。最后，SG Americas Securities LLC 在第三季度将其在 Tarsus Pharmaceuticals 的持股增加了 87.5%。SG Americas Securities LLC 目前拥有 7,242 股该公司的股票，价值 238,000 美元，此前在此期间又购买了 3,379 股。对冲基金和其他机构投资者持有该公司 90.01% 的股票。</p>
</div><h2>Tarsus Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.</p>
<div class="lb-trans"><p>Tarsus Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于在美国开发和商业化新型眼科治疗候选药物。该公司的主要产品候选药物是 XDEMVY，一种用于治疗由螨虫感染引起的睑板腺炎的新型治疗药物，以及用于治疗睑板腺疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Tarsus Pharmaceuticals</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>3 Must-Hold Stocks with Double-Digit Upside for 2025</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Micron: Why Now Is the Time to Be Brave</li>
<li>How to Invest in the FAANG Stocks</li>
<li>3 Stocks That Wall Street Insiders Can’t Stop Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Tarsus Pharmaceuticals</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>2025 年必须持有的三只股票，具有两位数的上涨潜力</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>美光：为什么现在是勇敢的时候</li>
<li>如何投资 FAANG 股票</li>
<li>三只华尔街内部人士无法停止购买的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><p>→ Viral Trump video released (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 释放病毒特朗普视频（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE0NQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=11145&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Tarsus Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tarsus Pharmaceuticals 吗？</h2>
</div><p>Before you consider Tarsus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Tarsus Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tarsus Pharmaceuticals 并不在名单上。</p>
</div><p>While Tarsus Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tarsus Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High  - Here's What Happened

Market Beat

Tarsus Pharmaceuticals（NASDAQ:TARS）创下新的 1 年高点 - 事情是这样的